1
|
Demir A, Mandel NM, Paydas S, Demir G, Er Ö, Turhal NS, Bavbek S, Eralp Y, Saip PM, Güler EN, Aydıner A, Oyan Uluç B, Kılıçkap S, Üskent N, Karadurmuş N, Kaplan MA, Yanmaz MT, Demir H, Alan Ö, Korkmaz T, Olgun P, Sönmez Uysal Ö, Altundağ K, Gündüz Ş, Günaldı M, Sarı M, Beypınar İ, Başaran G. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial. Balkan Med J 2020; 37:104-107. [PMID: 31970972 PMCID: PMC7094190 DOI: 10.4274/balkanmedj.galenos.2020.2019.11.143] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Background: The synthesis of CDK4/6 inhibitors with endocrine treatment in two series of treatment has been widely accepted as the standard for patients with estrogen receptor-positive metastatic breast cancer. In spite of this, the activity of CDK4/6 inhibitors in patients with metastatic breast cancer who have progressed despite receiving multiple lines of treatment is not well understood. Aims: To report the activity and safety of a CDK4/6 inhibitor (palbociclib) in patients in whom at least three lines of treatment for ER+ metastatic breast cancer had failed. Study Design: Multicenter retrospective observational cohort study. Methods: In this retrospective observational cohort study, we included 43 patients who received palbociclib after at least three lines of systemic treatment for ER+/HER2− metastatic breast cancer. Results: The median progression-free survival in our population was 7 months (25th-75th percentile, 4-10), and the median overall survival was 11 months (25th-75th percentile, 6-19). Although there were some adverse events, palbociclib was generally well tolerated, so dose reduction was needed for only six patients (14%). Conclusion: The efficacy of palbociclib among heavily treated hormone receptor-positive/HER2− patients with advanced breast cancer was acceptable in terms of clinical benefit, and it was generally well tolerated among this population.
Collapse
Affiliation(s)
- Atakan Demir
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | | | - Semra Paydas
- Department of Medical Oncology, Çukurova University School of Medicine, Adana, Turkey
| | - Gökhan Demir
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Özlem Er
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | | | | | - Yeşim Eralp
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Pınar Mualla Saip
- Department of Medical Oncology, İstanbul University Oncology Institute, İstanbul, Turkey
| | - Emine Nilüfer Güler
- Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Adnan Aydıner
- Department of Medical Oncology, İstanbul University Oncology Institute, İstanbul, Turkey
| | - Başak Oyan Uluç
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Sadettin Kılıçkap
- Department of Medical Oncology, Hacettepe University School of Medicine, Ankara, Turkey
| | - Necdet Üskent
- Clinic of Oncology, Anadolu Medical Center Hospital, Kocaeli, Turkey
| | - Nuri Karadurmuş
- Clinic of Medical Oncology T.C. Ministry of Health Gülhane Training and Research Hospital, Ankara, Turkey
| | - Mehmet Ali Kaplan
- Department of Medical Oncology, Dicle University School of Medicine, Diyarbakır, Turkey
| | | | - Hacer Demir
- Department of Medical Oncology Afyon Kocatepe University School of Medicine, Afyon, Turkey
| | - Özkan Alan
- Tekirdağ State Hospital, Tekirdağ, Turkey
| | - Taner Korkmaz
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| | - Polat Olgun
- Near East University Hospital, Lefkoşa, TRNC
| | | | | | | | - Meral Günaldı
- Clinic of Medical Oncology, Florya Medical Park Hospital, İstanbul, Turkey
| | | | - İsmail Beypınar
- Department of Medical Oncology Afyon Kocatepe University School of Medicine, Afyon, Turkey
| | - Gül Başaran
- Department of Medical Oncology, Acıbadem University, İstanbul, Turkey
| |
Collapse
|
2
|
Tanriverdi O, Menekse S, Teker F, Oktay E, Nur Pilanc K, Gunaldi M, Kocar M, Kacan T, Bahceci A, Avci N, Akman T, Cokmert S, Yesil-Cinkir H, Teoman Yanmaz M. The mean platelet volume may predict the development of isolated bone metastases in patients with breast cancer: a retrospective study of the Young Researchers Committee of the Turkish Oncology Group (TOG). J BUON 2016; 21:840-850. [PMID: 27685904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
PURPOSE To determine the predictive value of the mean platelet volume (MPV) and the MPV/platelet count ratio on the development of isolated bone metastasis in patients with breast cancer. METHODS A total of 121 previously untreated female patients with isolated bone metastases from breast cancer (group 1) were included in this retrospective cohort study. The patients enrolled in this study had similar age, biological subtypes, and duration of follow-up after diagnosis. Group 1 was compared with both 71 previously untreated women with breast cancer with no metastases at all (group 2) and 39 healthy women (group 3). Demographic data, laboratory tests and histological features of all of the patients in groups 1 and 2 were recorded and the study variables from each of the three groups were compared. RESULTS In group 1, the cut-off value (9.2 fL) for the MPV was determined and patients were stratified into 4 subgroups. The MPV was higher in group 1 than in either group 2 or group 3. Group 1 patients had a MPV of 8.8±3.1 fL (mean 5.1, range: 6.1-15.6) and the cut-off value for MPV was 9.2 fl. For patients in group 1, the MPV distribution was stratified into 4 groups as follows: group A included MPV values <6.08 fL, in group B values ranged from 6.09 to 8.46 fL, group C included values from 8.47 to 10.05 fL, and group D included patients with MPV values >10.06 fL. MPV and the presence of lymphovascular invasion were found to be independent risk factors for the development of isolated bone metastases. CONCLUSION We concluded that MPV can be used to predict the development of isolated bone metastases.
Collapse
Affiliation(s)
- Ozgur Tanriverdi
- Mugla Sitki Kocman University Faculty of Medicine, Department of Medical Oncology, Mugla, Turkey
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Güner ŞI, Yanmaz MT, Selvi A, Usul C. The High Effect of Chemomobilization with High-Dose Etopside + Granulocyte-Colony Stimulating Factor in Autologous Hematopoietic Peripheral Blood Stem Cell Transplantation: A Single Center Experience. Hematol Rep 2016; 8:6319. [PMID: 27103979 PMCID: PMC4815948 DOI: 10.4081/hr.2016.6319] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2015] [Revised: 03/13/2016] [Accepted: 03/13/2016] [Indexed: 12/22/2022] Open
Abstract
Autologous hematopoietic stem cell transplantation (auto-HSCT) provides hematopoietic support after high-dose chemotherapy and is the standard of care for patients with multiple myeloma (MM), chemo sensitive relapsed high or intermediate grade non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). However, yields of hematopoietic stem cells vary greatly between patients, and the optimal strategy to mobilize hematopoietic stem cells into peripheral blood for collection has not been defined yet. We investigated the efficacy and safety of chemo mobilization with an intermediate dose etoposide (VP-16; 200 mg/m2 on days 1-3) and granulocyte-colony stimulating factor (G-CSF)(5 µg/kg twice daily from day 4 through the final day of collection). We reviewed our institutional experience with 91 patients (71 MM, 12 HL, 8 NHL) mobilized with this regimen. VP-16 + G-CSF resulted in successful mobilization in 95.55% of the patients (on one patient stem cell collection with plerixafor was applied), including 76 patients (83.52%) whose stem cells were collected successfully in a single day. Collection was managed between min. D8 and max. D17. Patient age, gender, exposure to previous irradiation and chemotherapy, previous mobilization attempts, and disease characteristics were not considered during selection. Adverse effects of the regimen included supportive transfusions and fevers requiring hospitalization or intravenous antibiotics. VP-16 and G-CSF appears to be a safe and effective mobilization regimen for patients with multiple myeloma, non-Hodgkin’s lymphoma and Hodgkin’s lymphoma undergoing autologous stem cell transplantation, producing excellent stem cell yield with the majority of patients requiring 1 day of apheresis.
Collapse
Affiliation(s)
- Şebnem Izmir Güner
- Departments of Hematology, Istanbul Kemerburgaz University, Medical Park Bahcelievler Hospital , Istanbul, Turkey
| | - Mustafa Teoman Yanmaz
- Departments of Medical Oncology, Istanbul Kemerburgaz University, Medical Park Bahcelievler Hospital , Istanbul, Turkey
| | - Ahmet Selvi
- Departments of Pulmonary Medicine, Istanbul Kemerburgaz University, Medical Park Bahcelievler Hospital , Istanbul, Turkey
| | - Cigdem Usul
- Department of Medical Oncology, Istanbul Research and Education Hospital , Istanbul, Turkey
| |
Collapse
|
4
|
Yanmaz MT, Demir G, Erdamar S, Keskin S, Aydin MF, Guner SI. Epidermal growth factor receptor in CRC patients in the era of the RAS. Hepatogastroenterology 2015; 62:40-44. [PMID: 25911864] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Abstract
The aim of this study was to investigate EGFR expression patterns and the effect of EGFR expression on stage, prognosis and response to conventional chemotherapy agents other than monoclonal antibodies in CRC patients. This study included 59 metastatic CRC patients. The expression of EGFR was quantified by immunochemistry in biopsy specimens that were obtained before treatment was initiated. The cases were considered to be positive for EGFR if >1% of the tumor cells had complete circumferential membranous staining. The median age of the patients was 54.6 years, and 59% of the patients were male. Twenty-six patients presented with stage IV disease, and the remaining patients developed distant metastasis during follow-up. Fifty-one patients were treated with regimens containing irinotecan. The numbers of patients with EGFR expression in the primary tumors, the metastatic lymph nodes and the normal colonic tissue were 34 (65.4%), 10 (76.9%) and 34 (65.4%) respectively. The initial disease stage and lymph node stage were correlated with EGFR expression (p<0.05). Additionally, EGFR positivity was correlated with a statistically significant reduction in the response rate to chemotherapy, the overall survival (21 vs. 28 months) and the progression-free survival (15 vs. 22 months) in metastatic patiens treated with chemotherapy other than targeted therapies. In conclusion, EGFR expression in correlated with stage in all CRC patients and response to chemotherapy and survival in metastatic CRC patients.
Collapse
|